Fischer Medical Ventures Limited has informed the exchange on the receipt of Monitoring agency report for the quarter ended 31.03.2025
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Infomerics Valuation and Rating has submitted its Monitoring Agency Report on Fischer Medical Ventures' Rs. 358.46 crore preferential issue, comprising 1.03 crore equity shares (Rs. 241.06 crore) and 50.17 lakh fully convertible warrants (Rs. 117.40 crore) at Rs. 234 each. All equity shares have been allotted, while warrants have only brought in the 25% application money so far (Rs. 29.35 crore), taking total receipts to Rs. 270.40 crore. Of this, Rs. 269.20 crore has been deployed: Rs. 250.41 crore into growth objectives — Rs. 220.91 crore invested in wholly-owned subsidiary Time Medical International Ventures (India) and Rs. 29.51 crore in Flynncare Health Innovations — and Rs. 18.79 crore for general corporate purposes (mainly Rs. 15.93 crore in merchant banker fees, plus lease deposits, advertising and rent). The remaining Rs. 1.20 crore sits in a sweep/fixed deposit account.
No deviation from stated objects and no implementation delays — a clean compliance report. Funds are flowing into MRI/imaging and preventive healthcare subsidiaries, signaling expansion focus. Investors should note that Rs. 88.05 crore is still pending from warrant conversions (25% received, balance within 18 months), which could dilute equity later or strengthen the balance sheet if exercised.